EMV Capital, a London-based early-stage venture investor focused on B2B companies in the industrial high-tech, energy, circular economy, smart cities, and transportation sectors, acquired a majority stake in Vortex Biosciences, a biotechnology company in Pleasanton, California. Financial terms were not disclosed. “We will apply this new funding to achieve an expanded menu of downstream integration. Our vision at Vortex is to improve Cancer detection and therapy by providing the best CTC sample workflow from a standard tube of blood." Robert Englert, Vortex CEO.